.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Queensland Health
Cipla
Farmers Insurance
Boehringer Ingelheim
Fuji
Harvard Business School
Argus Health
Baxter

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,442,830

« Back to Dashboard

Claims for Patent: 7,442,830

Title:Proteasome inhibitors
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Olhava; Edward J. (Cambridge, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee: Millenium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/890,412
Patent Claims: 1. A compound of formula (I): ##STR00009## or a pharmaceutically acceptable salt or boronic acid anhydride thereof, wherein: Z.sup.1 and Z.sup.2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid completing agent; and Ring A is selected from the group consisting of ##STR00010##

2. The compound of claim 1 selected from the group consisting of: [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbu- tyl]boronic acid; [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]boronic acid; [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]bo- ronic acid; [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

3. The compound of claim 1, which is a mannitol ester of a boronic acid compound selected from the group consisting of: [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbu- tyl]boronic acid; [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]boronic acid; [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]bo- ronic acid; [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A method for treating cancer, comprising administering to a patient in need of such treatment a pharmaceutical composition according to claim 4.

6. The compound [(1R)-1({[(2,4-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

7. The compound [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boroni- c acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

8. The compound [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]boroni- c acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

9. The compound [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]-acetyl{amino)-3-methylbutyl]b- oronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.

10. The compound [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl{-amino)-3-methylbutyl]b- oronic acid or a pharmaceutically acceptable salt or boronic acid anhydride thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Argus Health
Healthtrust
Cipla
US Department of Justice
Express Scripts
Teva
Federal Trade Commission
Merck
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot